Articles about Immune Design

Merck research chief Roger Perlmutter touts Seattle biotech strength after $300M Immune Design deal

Two months after Merck acquired Seattle-based biotech Immune Design for $300 million, the president of Merck Research Laboratories, Roger Perlmutter,… Read More

Drug giant Merck pays $300M to acquire Seattle biotech company Immune Design

Merck, one of the world’s largest drugmakers, agreed to buy Seattle-based biotechnology company Immune Design for $300 million in cash.… Read More

Cancer research company Immune Design raises $60M in IPO

Trading on the NASDAQ under the ticker IMDZ, Seattle biotech company Immune Design today priced its initial public offering at… Read More

Cancer research company Immune Design sets IPO range at $12 to $14 per share

Seattle biotechnology company Immune Design, which is working on novel technologies that activate the body’s immune system to fight cancer,… Read More

Cancer research startup Immune Design files for $60 million IPO

Immune Design Corp., a Seattle biotechnology company developing technologies to activate the body’s immune system to fight cancer, has filed… Read More

Cancer research startup Immune Design pulls in $32.5 million, plans to raise more

Immune Design has reeled in $32.5 million in venture capital financing, with plans to raise up to $16.5 million more… Read More